# Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer

> **NCT01985841** · PHASE2 · TERMINATED · sponsor: **Hellenic Oncology Research Group** · enrollment: 34 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bevacizumb
- **DRUG:** 5-Fluorouracil
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01985841
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Due to poor accrual
- **Last updated:** 2015-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01985841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01985841, "Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01985841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*